# Mixed Venous and Arterial Pco,

J. D. S. McEVOY, N. L. JONES, E. J. M. CAMPBELL

British Medical Journal, 1974, 4, 687-690

### **Summary**

The rebreathing method of measuring oxygenated mixed venous Pco<sub>2</sub> (Pvco<sub>2</sub>) was originally introduced as a bloodless way to estimate arterial Pco, (Paco,). It has become common practice to subtract 6 mm Hg from the Pvco<sub>2</sub> to obtain the Paco<sub>2</sub> but there are many circumstances in which this leads to an overestimate of the Paco<sub>2</sub>. Measurements of Pvco<sub>2</sub> and Paco<sub>2</sub> in 19 patients have shown that a better approximation to Paco2 under normal conditions of cardiac output and arterial O2 saturation is Paco<sub>2</sub> = 0.8 Pvco<sub>2</sub>. These studies also showed that the  $P\overline{v}co_2 - Paco_2$  difference may be much wider, particularly in the presence of arterial unsaturation and a low cardiac output.

The factors governing the venoarterial Pco, difference are reviewed and their magnitude is calculated to emphasize the complementary roles of measurements of Pvco2 and Paco2 in the assessment of patients with cardiorespiratory disease.

#### Introduction

Hackney et al. (1958) introduced the rebreathing method for measuring mixed venous Pco<sub>2</sub> into clinical practice as a means of estimating arterial Pco2. The principle they used was one which was introduced early this century (Plesch, 1909), in which the lung is used as an aerotonometer so that the gases during rebreathing reach equilibrium with those in the mixed venous blood. Hackney et al. (1958) and Campbell and Howell (1960) examined the accuracy with which rebreathing methods could be used to estimate arterial Pco<sub>2</sub> (Paco<sub>2</sub>). Both these groups reported that Paco2 was on average 6 mm Hg less than "oxygenated" mixed venous Pco<sub>2</sub> (Pvco<sub>2</sub>), and since their work the subtraction of 6 mm Hg from the rebreathing equilibrium Pco<sub>2</sub> has become an accepted way of estimating Paco<sub>2</sub>. Theoretical considerations and also our experience, however, indicate that the difference between Pvco2 and Paco2 (the  $\overline{v}$  – a Pco<sub>2</sub> difference) may be greater than 6 mm Hg. This paper reports on an experimental and theoretical examination of the different but complementary uses of Pvco, and Paco, measurements.

## **Terminology**

Arterial PCO2.—This is measured in samples of arterial blood using the CO<sub>2</sub> electrode or some similar method.

"True" Mixed Venous PCO2.—This is the PCO2 of blood samples from the pulmonary artery (not measured in this study).
"Oxygenated" Mixed Venous PCO2.—This is the classical term

used to describe the Pco2 of mixed venous blood in which the haemoglobin is fully saturated with O2. The CO2 content of this blood

McMaster University: Regional Respiratory Laboratory, St. Joseph's Hospital, Hamilton, Ontario

J. D. S. McEVOY, M.R.C.P., M.R.A.C.P., Sepior Resident (Present address: Chermside Hospital, Brisbane, Australia) N. L. JONES, M.D., F.R.C.P., Professor of Medicine E. J. M. CAMPBELL, M.D., F.R.C.P., Chairman, Department of Medicine

is the same as true mixed venous blood but the Pco2 is higher because oxygenation of haemoglobin decreases buffering capacity and reduces the amount of CO<sub>2</sub> carried as carbaminohaemoglobin—the Christiansen-Douglas-Haldane (C.D.H.) effect (Christiansen et al., 1914). This is the Pco2 which nearly all "indirect" rebreathing or breath-holding methods aim to measure by using the lungs as an aerotonometer (see below).

Rebreathing PCO2.—This is recorded during rebreathing of a CO<sub>2</sub> mixture and measured when the CO<sub>2</sub> record shows CO<sub>2</sub> equilibrium between the rebreathing bag, the lungs, and the pulmonary capillary blood (Campbell and Howell, 1960, 1962).

The rebreathing Pco<sub>2</sub> as defined above is taken to be the oxygenated mixed venous Pco<sub>2</sub>. For the bulk of this paper this assumption is accepted, though it is re-examined below.

#### Material and Methods

Studies were performed on 19 patients, 11 with chronic hypercapnia and 8 with a normal Paco<sub>2</sub> (see table). The nature of the procedure was explained to all the patients, the fact that the investigation was for research purposes being pointed out, and their informed consent was obtained.

Spirometric measurements were performed on the day of the study. A Teflon arterial catheter was inserted percutaneously into the brachial artery. The patient sat upright and breathed through a valve box of low dead space. The CO<sub>2</sub> concentration in the mixed expired gas and the end tidal CO2 were continuously measured to establish a steady state of CO<sub>2</sub> output. After attaining apparently steady-state conditions as indicated by a variation in the expired CO<sub>2</sub> and O<sub>2</sub> concentrations of less than  $\pm$  0.2% arterial blood was sampled and the rebreathing Pco<sub>2</sub> estimated.

Rebreathing was performed with mixtures of CO2 and O2 in a rubber bag of nominal 5-litre capacity. The volume and CO<sub>2</sub> concentration of the gas in the bag were varied to achieve a sustained equilibrium in the rebreathing system. Up to six rebreathings were required to obtain a CO2 equilibrium fulfilling the criteria set out below; at least half a minute was allowed to elapse between successive rebreathes in order to avoid the competing effects of CO2 accumulation during rebreathing and the transient stimulus to breathing produced by it. Equilibration of CO2 was recognized by the appearance of a "plateau" in the record of CO<sub>2</sub> concentration at the mouth; this plateau represents a period during rebreathing when there is no change in the CO<sub>2</sub> concentration of gas passing to and fro between the rebreathing bag and the lungs and which is sustained over several breaths, indicating a lack of net movement of CO2 either into or out of the system. Previous studies (McEvoy et al., 1973) indicated that the following criteria were necessary to achieve CO<sub>2</sub> equilibrium and a "true plateau."

- (a) The CO<sub>2</sub> record should reach plateau conditions within 15 seconds of the onset of rebreathing.
- (b) The plateau should be sustained for at least three complete respiratory cycles.
- (c) The plateau should not show a tidal fluctuation of more than  $\pm 1$  mm Hg.

At least two estimates satisfying these criteria were obtained in 16 patients.

Measurements of CO<sub>2</sub> were made with an infrared CO<sub>2</sub> analyser (Godart Capnograph); the 90% response time of the analyser and sample system was 0.74 second. The analyser was calibrated with gases containing three concentrations of CO<sub>2</sub> in 40% oxygen, previous studies having shown that the rebreathing of CO<sub>2</sub> mixtures in oxygen leads to a concentration of 40% oxygen at the end of the rebreathing period. The calibrating gases were analysed with the Lloyd-Haldane apparatus. Oxygen was analysed in the mixed expired gas using a Servomex paramagnetic O<sub>2</sub> analyser, whose accuracy was checked with calibrated gases previously analysed in the Lloyd-Haldane apparatus.

Arterial blood was analysed with a pH meter (Radiometer) and with Severinghaus  $O_2$  and  $CO_2$  electrodes (Radiometer BMS-3). The electrode system was calibrated regularly with gases analysed in the Lloyd-Haldane apparatus and with tonometered blood. The mean ( $\pm$  S.D.) differences for duplicate analyses were  $0.08 \pm 1.10$  mm Hg for  $CO_2$  and  $0.79 \pm 0.50$  mm Hg for  $O_3$ .

#### Results

In spite of our care in establishing "steady-state" criteria for  $CO_2$  and  $O_2$  concentrations in the expired gas before rebreathing, when analysing the results it became apparent that several studies had been carried out in an "unsteady state," with high values for the respiratory exchange ratio and arterial pH (see table). These patients are identified in fig. 1 and are omitted from the statistical analyses; wide  $\overline{v} - a$  PCO<sub>2</sub> differences were found in these studies.

The differences between mixed venous  $Pco_2$  and arterial  $Pco_2$  varied from 4 mm to 25 mm Hg (table, fig. 1). The difference was greatest at high levels of  $Pco_2$ ; high values were also associated with the presence of cardiac failure and arterial desaturation (fig. 1). The  $\bar{v}-a$   $Pco_2$  difference for all patients excluding those showing a respiratory exchange ratio of over 1.0 is expressed as:  $Paco_2 = 0.68$   $P\bar{v}co_2 + 7.4$  mm Hg (r = 0.904; S.E. 3.01). When the two patients with cardiac failure are excluded the regression equation is  $Paco_2 = 0.78$   $P\bar{v}co_2 \pm 2.5$  mm Hg (r = 0.904; S.E. 2.50). These equations suggest that a better approximation to arterial  $Pco_2$  is obtained by taking 0.8  $P\bar{v}co_2$  rather than  $P\bar{v}co_2-6$ .




FIG. 1—Experimental results. Symbols other than (O) represent arterial  $O_2$  saturation of less than 0-80 ( $\blacksquare$ ), patients with clinical evidence of right heart failure ( $\triangle$ ), and studies in which respiratory exchange ratio was above  $1\cdot0$  ( $\Diamond$ ). Regression equation omits last two groups.

## Discussion

The results in our patients in general bore out our experience—that is, the mixed venous PCO<sub>2</sub> was more than 6 mm Hg higher than the arterial PCO<sub>2</sub>. Thus we critically re-examined this previously accepted difference.

FACTORS AFFECTING VENOARTERIAL PCO2 DIFFERENCE

The mixed venous minus arterial PCo<sub>2</sub> difference is determined, firstly, by the venoarterial CO<sub>2</sub> content difference and, secondly, by the CO<sub>2</sub> dissociation curve, which expresses the relationship between CO<sub>2</sub> pressure and CO<sub>2</sub> content. The former represents the balance between pulmonary CO<sub>2</sub> excretion and cardiac output; the latter is influenced by blood haemoglobin, oxygenation, and the level of Pco<sub>2</sub> as detailed below. When taking usual values for these variables found in a healthy subject at rest the mixed venous minus arterial Pco<sub>2</sub> at rest is closer to 10 mm Hg than 6 mm Hg (fig. 2). One or more of the above factors may lead to the difference being increased to over 10 mm Hg. We examined these effects using the CO<sub>2</sub> dissociation curves of McHardy (1967) and Kelman (1967).




FIG. 2—Carbon dioxide dissociation curves for different values of arterial  $O_2$  saturation (So<sub>2</sub>). Points a, v, and R represent arterial blood, true mixed venous blood, and oxygenated mixed venous blood respectively when arterial blood is fully saturated with  $O_2$ ; a', v', and R' represent same relationships when arterial  $O_2$  saturation is 0.75. Arteriovenous  $CO_2$  content difference is constant at 4 ml/100 ml. Relationships for two levels of arterial  $PCO_2$ , 40 and 60 mm Hg, are shown.

Increasing Blood Pco<sub>2</sub>.—The CO<sub>2</sub> dissociation curve is convex upwards; the Pvco<sub>2</sub> — Paco<sub>2</sub> difference becomes wider for a given venoarterial CO<sub>2</sub> content difference in higher regions of the curve. This is illustrated in fig. 2, which shows that at a Paco<sub>2</sub> of 40 mm Hg the mixed venous Pco<sub>2</sub> is 50 mm Hg for a venoarterial CO<sub>2</sub> content difference of 4 ml/100 ml; when Paco<sub>2</sub> is 60 mm Hg the mixed venous Pco<sub>2</sub> is 72.5 mm Hg, the v — a Pco<sub>2</sub> difference increasing to 12.5 mm Hg.

Reduced Arterial Oxygen Saturation (fig. 2).—When the arterial blood is unsaturated the Pco<sub>2</sub> is lower for any given CO<sub>2</sub> content by virtue of the C.D.H. effect (compare a' and a in fig. 2). As the rebreathing method estimates the oxygenated mixed venous Pco<sub>2</sub> the  $\bar{v}$  — a Pco<sub>2</sub> rises (compare the horizontal difference a-R with a'-R' in fig. 2). This effect is somewhat greater higher up the dissociation curve; at a PaCO<sub>2</sub> of 60 mm Hg the rebreathing Pco<sub>2</sub> is 76 mm Hg, a difference of 16 mm Hg (fig. 2).

Increased Venoarterial CO<sub>2</sub> Content Difference ( $\overline{v}$  – a CCO<sub>2</sub>). —When the Fick principle is applied to CO<sub>2</sub> exchange in the lung  $\overline{v}$  – a CCO<sub>2</sub> = CO<sub>2</sub> output/cardiac output. Thus in any condition in which the cardiac output is low  $\overline{v}$  – a CCO<sub>2</sub> is increased, leading to a rise in the  $\overline{v}$  – a PCO<sub>2</sub> difference. The magnitude of this effect is shown in fig. 3 for a cardiac output which is half normal—that is, the  $\overline{v}$  – a CO<sub>2</sub> content difference is twice normal at 8 ml/100 ml. At an arterial PCO<sub>2</sub> of 40 mm Hg P $\overline{v}$ CO<sub>2</sub> is 60.5 mm Hg, showing a  $\overline{v}$  – a PCO<sub>2</sub> difference of 20.5 mm Hg. Thus a fall in cardiac output has a marked influence on the  $\overline{v}$  – PCO<sub>2</sub> difference.

Reduced Haemoglobin Concentration.—A reduced blood

haemoblogin increases the  $\overline{v}-a$  PCO<sub>2</sub> difference for any given CO<sub>2</sub> content difference, particularly at low values of PCO<sub>2</sub>. This effect is shown in fig. 4, which indicates that at a haemoglobin level of 10 g/100 ml, an arterial PCO<sub>2</sub> of 40 mm Hg, and a CO<sub>2</sub> content difference of 4 ml/100 ml PvCO<sub>2</sub> is 53 mm Hg or 3 mm higher than at a haemoglobin of 15 g/100 ml.




FIG. 3—Effect of increase in arteriovenous  $CO_2$  content difference to 8 ml/100 ml; arterial blood fully oxygenated. Symbols as in fig. 2.




FIG. 4—Carbon dioxide dissociation curves of whole blood showing effect of haemoglobin levels.

We may summarize (fig. 5) by stating, firstly, that if equilibration is obtained with oxygenated mixed venous blood the equilibrium PCO<sub>2</sub> (PvCO<sub>2</sub>) will be 10 mm Hg above PaCO<sub>2</sub>, given normal cardiac output, O<sub>2</sub> saturation, and haemoglobin; secondly, that the PvCO<sub>2</sub> — PaCO<sub>2</sub> difference is likely to be greater than 10 mm Hg if PCO<sub>2</sub> is high and arterial O<sub>2</sub> saturation is reduced (both being common in respiratory failure); if cardiac output is low (often a complicating factor in clinical practice); and, finally, if there is anaemia. Our studies in patients bore out these considerations (table, fig. 1).

In addition to these physiological factors the difference between mixed venous PCo<sub>2</sub> and arterial PCo<sub>2</sub> may be widened by a number of factors which are more technical than physiological in nature. Furthermore, the previously established difference of approximately 6 mm Hg may be accounted for by such factors.

Hackney et al. (1958) studied 60 patients with heart or lung disease and found that  $P\overline{v}co_2 - Paco_2$  varied from 1 to 11 mm Hg even when Paco<sub>2</sub> was high; in one of their patients

Paco<sub>2</sub> was 90.8 mm Hg and Pvco<sub>2</sub> only 1 mm Hg higher. Such a venoarterial Pco<sub>2</sub> difference implies an impossibly high resting cardiac output and must be explained largely on technical factors.




FIG. 5—Theoretical relationship between  $P\overline{v}co_2$  and  $Paco_2$  at normal resting venoarterial  $CO_2$  content difference  $(C\overline{v} - aco_2 = 4 \text{ ml/100 ml})$ , Hb of 15 g/100 ml, and  $O_2$  saturation of 0.95 (———) showing (1) effect of doubling  $C\overline{v} - aco_2$  to 8 ml/100 ml (————) keeping Hb and  $O_2$  saturation constant, (2) effect of lowering  $SaO_2$  saturation to 0.80 keeping Hb 15 g/100 ml and  $C\overline{v} - aco_2$  at 4 ml/100 ml (——————), and (3) effect of lowering Hb to 10 g/100 ml keeping  $Cv - aco_2 + aco_2 +$ 

In the rebreathing techniques described by Collier (1956) care was taken to avoid the effects of recirculation during rebreathing, but an early and brief CO<sub>2</sub> "plateau" appears from later work to lead to an underestimate of Pvco<sub>2</sub> (Jones et al., 1967). Thus the plateau Pco<sub>2</sub> values reported by Hackney et al. (1958) often may have represented transient equilibration between the bag CO<sub>2</sub> and the alveolar CO<sub>2</sub> without equilibration with mixed venous CO<sub>2</sub>; this would be expected to lead to a Pvco<sub>2</sub> value closer to alveolar and thus arterial Pco<sub>2</sub> than the true venous Pco<sub>2</sub>.

Campbell and Howell (1960) shared Collier's concern to avoid overestimation of Pvco2 through the recirculation of blood with high CO<sub>2</sub> content and accepted rebreathing plateau which did not last beyond 10 seconds (Campbell, 1974). In their 15 patients, 11 of whom had lung disease, Campbell and Howell found a mean difference between Pvco2 and Paco2 of 6.1 mm Hg when Paco<sub>2</sub> ranged from 16 to 73.5 mm Hg. For the same reasons we now believe that the measurements of Pvco. using their method also lead to underestimates. This is supported by a figure in their paper which shows a rebreathing plateau which lasts for only one complete breath and represents a "phase reversal" of CO<sub>2</sub> (a pattern in CO<sub>2</sub> analysed at the mouth which changes from the CO<sub>2</sub> being higher in the rebreathing bag than in the lungs to one in which the CO<sub>2</sub> is higher in the lungs than in the bag). This phase-reversal pattern occurs long before recirculation could have raised the true Pvco2; to be certain of equilibrium with pulmonary capillary blood a plateau should last for at least two complete respiratory cycles and until at least 15 seconds after the start of rebreathing. We know that recirculation in a resting subject is unimportant until after 15 seconds (Sowton et al., 1958), and in our experience it is unusual to obtain plateau conditions before 10 seconds in most patients with severe airway obstruction.

Lowering of Paco<sub>2</sub> due to transient hyperventilation may be associated with arterial puncture even when great care is taken to minimize anxiety or discomfort. As body CO<sub>2</sub> stores are large the fall in mixed venous Pco<sub>2</sub> lags behind the fall in

Clinical and Experimental Data on Patients Studied

Case No.	Age (Years)	Sex	Body Surface Area (m²)	Diagnosis	Hb (g/100 ml)	% Predicted FEV <sub>1</sub>	Sao <sub>2</sub>	Pvco <sub>2</sub> (mm Hg)	Paco <sub>2</sub> (mm Hg)	Pvco <sub>2</sub> – Paco <sub>2</sub> (mm Hg)	Respiratory Exchange Ratio (R.Q.)
1	45	F.	1.30	Bronchiectasis, recurrent cardiac failure	17·4 17·2	17 20	0·91 0·94	83 72	58 55	25 17	0·94 0·83
2	50	М.	1.66	Chronic bronchitis {	17·5 17·3 17·2	46 20 24	0·93 0·86 0·91	58 65 68	43 53 54	15 12 14	1·09 0·90
3	53	M.	1.75	Chronic bronchitis	17·2 17·2 15·5	14 26	0.76 0.83	84 64	65 56	19 19 8	0·75  0·85
4 5	74 71	M. M.	1·77 1·94	Chronic bronchitis Chronic bronchitis	12·5 16·4	20 32	0·90 0·93	59 54	46 44	13 10	1·13 0·86
6	58	M.	2.08	Chronic bronchitis {	18·1 17·0	31 40	0·81 0·86	63 65	46 55	17 10	0·80 0·77
7 8	62 66	M. M.	2·13 1·49	Chronic bronchitis Chronic bronchitis	17·2 16·6	48 20	0·93 0·91	63 59	52 49	11 10	0·97 1·00
9 10	66 72	M. M.	1·77 1·84	Chronic bronchitis and emphysema Chronic bronchitis	11·2 17·3	19 51	0·75 0·88	78 <b>60</b>	64 53	14 7	0·90 0·85
11 12	54 58	M. M.	2·12 1·86	Chronic bronchitis Chronic bronchitis and mitral stenosis	16·3 15·5	43 77	0·88 0·95	61 55	47 44	14 11	0·89 0·76
13 14	56 61	M. M.	1·97 1·65	Chronic bronchitis, emphysema Chronic bronchitis, mitral stenosis, cardiac failure	15·3 15·4	75 19	0·95 0·94	42 45	27 34·5	15 10·5	1·27 1·00
15 16	50 59	M. M.	1·74 1·80	Bronchiectasis Chronic bronchitis	12·9 16·1	64 59	0·93 0·93	44 47	40	4	0.74
17	49	M.	1.88	Chronic bronchitis and pulmonary fibrosis	18-0	19	0.74	47 48	34·5 41·5	12·5 6·5	1·12 0·85
18 19	48 53	F. F.	1·54 1·74	Pulmonary fibrosis Mitral incompetence	11·8 13·0	84 87	0·96 0·94	47 47	38 36	9 11	0·84 0·91

Paco<sub>2</sub>, leading to an increased difference between Pvco<sub>2</sub> and Paco<sub>2</sub>. Such hyperventilation will also lead to high values for the respiratory exchange ratio and arterial pH as found in several of our patients (table). Finally, a true difference may exist between the rebreathing Pco2 and the Pco2 in venous blood. There is evidence that such a difference may exist during exercise (Jones et al., 1967, 1969) but at rest it is insignificant and certainly cannot be more than 2 mm Hg even in patients with chronic airway obstruction and respiratory failure (McEvoy et al., 1973).

The fact that many mechanisms may effect the prediction of Paco<sub>2</sub> from measurements of Pvco<sub>2</sub> may at first sight appear to reduce the value of measurements of Pvco2 in clinical practice. We do not believe that this is so. The two measurements really are complementary. Under conditions in which the difference between them may be increased or unpredictable it can by no means be taken as axiomatic that the arterial Pco<sub>2</sub> is preferable on either technical or physiological or clinical grounds. It is true that the rebreathing method for measuring Pvco2 and estimating Paco<sub>2</sub> was introduced at a time when the estimation of arterial blood gases was time consuming and beset by appreciable technical error. By contrast blood-gas electrodes are now commonplace in all hospitals in which seriously ill respiratory patients are cared for and the measurement of mixed venous Pco, may be thought to have lost its value. The following points may, however, be adduced to improve the appreciation of their relative technical, physiological, and clinical places. The measurement of Pvco2 is simple, rapidly performed by relatively unskilled personnel, and may be repeated often. The reproducibility and accuracy are close to those obtained in measurements of Paco<sub>2</sub>. From the physiological point of view Pvco<sub>2</sub> is less apt to be affected by transient hyperventilation. The argument that Pvco<sub>2</sub> is affected by mechanisms additional to those influencing Paco2 may be turned to advantage through an understanding of their importance. For example, the contribution of a low cardiac output to the total clinical picture in a patient with respiratory failure may be recognized through its effect on CO<sub>2</sub> transport. Though arterial Pco<sub>2</sub> unquestionably reflects respiratory function mixed venous Pco<sub>2</sub> reflects the sum total effects of all mechanisms clearing CO2 from extracellular fluid and is a better approximation to the Pco2 of the extracellular fluid.

Thus the clinical importance of measurements of Pvco is based on the following reasoning. Firstly, in patients in whom Paco<sub>2</sub> is not greatly raised—that is, those in whom alveolar ventilation is not greatly impaired—Pvco2 will give an accurate estimate of Paco2, which is not much influenced by transient hyperventilation. Secondly, in patients in respiratory failure the Pvco<sub>2</sub> reflects the adequacy of all CO<sub>2</sub> transport mechanismsalveolar ventilation, pulmonary gas exchange, cardiac output, and carriage of CO2 in blood. Furthermore, provided adequate criteria of equilibration are met it will never lead to an underestimate of Paco<sub>2</sub>; a raised Pvco<sub>2</sub> will thus direct attention to all mechanisms rather than to alveolar ventilation alone. Finally, when used in conjunction with measurements of Paco2 it will allow some assessment of the adequacy of cardiac output.

Requests for reprints should be addressed to: Dr. N. L. Jones, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario.

## References

Campbell, E. J. M., and Howell, J. B. L. (1960). British Medical Journal, 1, 458. Campbell, E. J. M., and Howell, J. B. L. (1962). British Medical Journal,

Campbell, E. J. M. (1974). Unpublished.

Campbell, E. J. M. (1974). Unpublished.
Christiansen, J., Douglas, C. G., and Haldane, J. S. (1914). Journal of Physiology, 48, 244.
Collier, C. R. (1956). Journal of Applied Physiology, 9, 25.
Hackney, J. D., Sears, C. H., and Collier, C. R. (1958). Journal of Applied Physiology, 12, 425.
Jones, N. L., et al. (1967). Clinical Science, 32, 311.
Jones, N. L., et al. (1969). Journal of Applied Physiology, 27, 356.
Kelman, G. R. (1967). Respiratory Physiology, 3, 111.
McEvoy, J. D., Jones, N. L., and Campbell, E. J. (1973). Journal of Applied Physiology, 35, 542.
McHardy, G. J. R. (1967). Clinical Science, 32, 299.
Plesch, J. (1909). Archiv für experimentelle Pathologie und Therapie, 6, 380.
Sowton, E., et al. (1968). Cardiovascular Research, 2, 341.